Aricept Lawsuit Filed To Force FDA Action On Petition to Ban High Dose

feature photo

By: Austin Kirk | Published: September 6th, 2012

The consumer watchdog group Public Citizen has filed a lawsuit against the FDA, seeking to force the federal drug regulatory agency to act on a petition filed to recall approval for high doses of Aricept, a medication for treatment of Alzheimer’s disease. 

The Aricept lawsuit was filed on September 5, asking a federal court to force the FDA to respond to Public Citizen’s petition, which was filed in May 2011.

The group asked the FDA to ban 23 milligram doses of Aricept and require new warnings on lower doses of the drug, due to the risk of serious and potentially life-threatening side effects. The complaint was filed because the FDA has taken no action on the petition to date.

“A primary function of the FDA is to protect citizens from harm caused by needlessly dangerous drugs, in this case a drug no more effective but significantly more dangerous than the lower doses of Aricept,” Public Citizen’s Health Research Group Director Dr. Sidney Wolfe said in a press release. “By ignoring Public Citizen’s petition for more than a year, the agency has ignored this responsibility and instead has chosen to support the profit interests of a large pharmaceutical company.”

According to Public Citizen, the side effects of Aricept in the 23 mg dose are far more toxic than at lower doses. In addition, there appears to be little clinical benefit from using the higher doses over the lower ones.

High doses of Aricept have been linked to a number of potential health risks, including lowered pulse, nausea, vomiting, diarrhea, urinary incontinence, fatigue, dizziness, agitation, confusion and anorexia, the group claims.

Only one clinical trial for 23 mg Aricept has been submitted to the FDA and Public Citizen notes that it failed to show that the 23 mg version was more effective than lower doses. In three out of four tests, there was no significant difference between the 10 mg and 23 mg doses in patients’ cognitive or functional level, and on the fourth test the difference was about 2 points on a scale of 100, which Wolfe says is not clinically important.

Aricept (donepezil) was developed by Pfizer and Eisai and was first approved for the treatment of Alzheimer’s disease in 1996. The 23 mg Aricept treatment was approved by the FDA over the objections of some of its own reviewers in 2010.

Tags: ,

There Are 3 Comments So Far • (Add Your Comments)

  1. I was prescribed Aricept for years because my doctor said I had Alzheimers. I ended up in Psych Ward and Nursing Home (due to aricept) , because I did NOT have Alzheimer’s. I was DIABETIC. I found out recently that ARICEPT SHOULD NEVER BE GIVEN TO DIABETICS. CAUSES ACETYLCHOLINE OVERLOAD!

  2. My mom was given aricept, now her mental mind is gone. She is 75 years old and should of never been given the medicine in the first place.

  3. My mother was very aware of what was going on and was able to get around and take care of herself but she started becoming a little forgetful and her new doctor placed on aricept and within a 3 months time period she stopped walking started, hallucinating and ended up in a nursing home where she died shortly after being placed on aricpet.

Post Your Comments

  • Have Your Comments Reviewed by a Lawyer

    Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published and will be confidential.
  • NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.